Stifel Financial’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Stifel Financial’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-3,010	Closed	-$14K	–	2619
2016 Q2	$14K	Buy	+3,010	New	+$13.6K	﹤0.01%	2493
2015 Q3	–	Sell	-22,892	Closed	-$1.13M	–	2498
2015 Q2	$1.13M	Sell	22,892 -53,063	-70%	-$3.17M	0.01%	1302
2015 Q1	$5.95M	Sell	75,955 -19,769	-21%	-$1.23M	0.03%	558
2014 Q4	$8.91M	Buy	95,724 +20,332	+27%	+$1.02M	0.05%	426
2014 Q3	$3.21M	Sell	75,392 -13,991	-16%	-$751K	0.03%	616
2014 Q2	$5.52M	Sell	89,383 -10,259	-10%	-$597K	0.05%	430
2014 Q1	$6.48M	Buy	+99,642	New	+$6.74M	0.06%	369

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stifel Financial's OREX Position: Q3 2016 in Review

Stifel Financial sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2016, closing a stake of 3,010 shares — an estimated $14K sold.

Stifel Financial first reported a position in OREX in Q1 2014 and held it in 7 quarters. The position peaked at $8.91M in Q4 2014. 55 funds tracked by Wall St. Rank hold OREX as of Q3 2016.

Stifel Financial reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
Stifel Financial sold 3,010 Orexigen Therapeutics, Inc. shares in Q3 2016, an estimated $14K.
Stifel Financial first reported a position in Orexigen Therapeutics, Inc. in Q1 2014 and held it in 7 quarters.
Stifel Financial's Orexigen Therapeutics, Inc. position peaked at $8.91M in Q4 2014.
55 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2016.

Based on Stifel Financial's 13F filing for Q3 2016, filed 15 Nov 2016.